PALI - Palisade Bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Carlsbad,
United States
Type: Equity
PALI price evolution
PALI
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.1 | $0.13 | $0.15 | $0.15 |
| Inventory | ||||
| Total current assets | $8.87 | $12.31 | $12.01 | $13.33 |
| Long term investments | ||||
| Property, plant & equipment | $0.12 | $0.15 | $0.17 | $0.21 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $9.34 | $12.87 | $12.65 | $14.05 |
| Current liabilities | ||||
| Accounts payable | $0.37 | $0.51 | $0.46 | $0.7 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.68 | $2.84 | $2.47 | $2.59 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2.73 | $2.92 | $2.59 | $2.74 |
| Shareholders' equity | ||||
| Retained earnings | -$132.6 | -$129.11 | -$125.03 | -$121.51 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.15 | $1.44 | $0.15 | $0.12 |
| Inventory | ||||
| Total current assets | $13.33 | $14.73 | $12.37 | $12.88 |
| Long term investments | ||||
| Property, plant & equipment | $0.21 | $0.31 | $0.11 | $0.01 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $14.05 | $15.76 | $12.51 | $13.05 |
| Current liabilities | ||||
| Accounts payable | $0.7 | $1.76 | $1.32 | $0.65 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.59 | $3.01 | $2.5 | $3.21 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2.74 | $3.28 | $5.15 | $3.28 |
| Shareholders' equity | ||||
| Retained earnings | -$121.51 | -$109.19 | -$94.64 | -$238.24 |
| Other shareholder equity | -$0 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $3.59 | $4.21 | $3.67 | $3.29 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.01 | -$0 | -$0 | -$0 |
| Net income | ||||
| Net income | -$3.49 | -$4.08 | -$3.53 | -$2.97 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.25 | $0.01 | ||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $13.1 | $15.31 | $11.74 | $10.69 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.01 | $2.41 | $20.64 | $0.03 |
| Net income | ||||
| Net income | -$12.3 | -$14.26 | -$26.62 | -$16.27 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.42 | $5.6 | $2.02 | $11.19 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4.39 | -$1.08 | -$1.16 | $0.05 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0 | -$0.01 | -$0.05 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $11.19 | $15.26 | $24.61 | $14.47 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.05 | $1.89 | $9.78 | $5.44 |
News
Fundamentals
| Market cap | $2.10M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.20M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$14.06M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.15 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$11.74 |
|---|---|
| ROA | -115.03% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.31 |
| Quick ratio | N/A |